META vs PFE: Which Is the Better Buy?
Side-by-side comparison of Meta Platforms, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Meta Platforms, Inc. · Communication Services
$671.34
+36.4% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
META has more upside to fair value
(+36.4%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
META |
PFE |
| Current Price |
$671.34 |
$26.33 |
| Fair Value Estimate |
$916.00 |
$33.85 |
| Upside to Fair Value |
+36.4%
|
+28.6%
|
| Market Cap |
$1,698.2B |
$149.8B |
| Forward P/E |
28.0x
|
19.3x
|
| EV / EBITDA |
16.5x
|
12.9x
|
| Price / Sales |
8.4x
|
2.4x
|
| Price / FCF |
36.8x
|
16.5x
|
| Revenue Growth YoY |
+23.8%
|
-1.2%
|
| Gross Margin |
82.0%
|
70.3%
|
| Operating Margin |
41.4%
|
24.7%
|
| Return on Equity |
30.6%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.72%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Meta Platforms, Inc. operates a leading global social media and technology platform primarily through its Family of Apps segment, which generates over 98% of its $201 billion 2025 revenue, driven by strong advertising growth. The company maintains a high-quality business with a durable competitive moat supported by network effects, brand strength, and intangible assets, reflected in a 30.6% retur…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
META |
PFE |
| Zone Low |
$687.00 |
$25.39 |
| Zone High |
$778.60 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|